Compare Emergent BioSolutions, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 441 Million (Micro Cap)
6.00
NA
0.00%
0.71
12.65%
0.76
Revenue and Profits:
Net Sales:
156 Million
(Quarterly Results - Mar 2026)
Net Profit:
7 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.39%
0%
-16.39%
6 Months
-10.14%
0%
-10.14%
1 Year
92.62%
0%
92.62%
2 Years
107.5%
0%
107.5%
3 Years
1.9%
0%
1.9%
4 Years
-70.99%
0%
-70.99%
5 Years
-85.18%
0%
-85.18%
Emergent BioSolutions, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-9.96%
EBIT Growth (5y)
-15.29%
EBIT to Interest (avg)
4.18
Debt to EBITDA (avg)
4.15
Net Debt to Equity (avg)
0.93
Sales to Capital Employed (avg)
0.76
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
96.07%
ROCE (avg)
9.11%
ROE (avg)
7.50%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
0.76
EV to EBIT
7.39
EV to EBITDA
3.97
EV to Capital Employed
0.86
EV to Sales
1.09
PEG Ratio
0.04
Dividend Yield
NA
ROCE (Latest)
11.62%
ROE (Latest)
12.65%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 52 Schemes (29.34%)
Foreign Institutions
Held by 71 Foreign Institutions (7.52%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
156.10
148.70
4.98%
Operating Profit (PBDIT) excl Other Income
34.60
6.90
401.45%
Interest
11.00
14.70
-25.17%
Exceptional Items
8.40
-24.60
134.15%
Consolidate Net Profit
6.80
-54.60
112.45%
Operating Profit Margin (Excl OI)
67.30%
-111.60%
17.89%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 4.98% vs -35.66% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 112.45% vs -206.64% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
742.90
1,043.60
-28.81%
Operating Profit (PBDIT) excl Other Income
208.50
53.60
288.99%
Interest
59.30
71.00
-16.48%
Exceptional Items
-22.30
-50.30
55.67%
Consolidate Net Profit
52.60
-190.60
127.60%
Operating Profit Margin (Excl OI)
148.30%
-56.00%
20.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -28.81% vs -0.54% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 127.60% vs 74.94% in Dec 2024
About Emergent BioSolutions, Inc. 
Emergent BioSolutions, Inc.
Pharmaceuticals & Biotechnology
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
Company Coordinates 
Company Details
400 Professional Dr Ste 400 , GAITHERSBURG MD : 20879-3457
Registrar Details






